Robert Gorman Net Worth

Robert Gorman biography

Robert Gorman serves as Director of the Company. He was initially designated as director on October 17, 2019 by Ampersand as holder of Series A Convertible Preferred Stock, $0.01 par value per share (“Series A Preferred Stock”) and thereby appointed and elected to the Board and was re-designated as director by Ampersand as holder of Series B Preferred Stock and thereby re-appointed and re-elected to the Board effective January 15, 2020. On January 22, 2020, the Company named Mr. Gorman to the Compensation Committee and the Regulatory Compliance Committees. On April 16, 2020, Mr. Gorman resigned as a member of the Compensation Committee and was appointed as Chairman of the Board. Mr. Gorman’s experience includes over 30 years in healthcare leadership positions. The majority of his career has been in the laboratory services industry with both public and private companies. After leaving public accounting, he served as Operations Controller for Home Medical Systems, Inc., a company focused on the roll-up of the durable medical equipment business in the United States and sold to Beverly Enterprises. He joined Central Diagnostic Laboratory, the largest independent laboratory at the time, as East Coast Controller, which was acquired by Corning Clinical Laboratory (now known as Quest Diagnostics Incorporated). He spent over 20 years at Quest Diagnostics Incorporated. While at Quest Diagnostics Incorporated, he held various leadership roles including responsibility for the New York and New England laboratories and the East Region, and he ultimately became the Vice President of U.S. operations. Mr. Gorman serves as a consultant for MLC, LLC, for which he is also the general partner. Mr. Gorman has served on several for profit and not for profit boards, including for Eurofins’s subsidiary Boston Heart Diagnostics Corporation from January 2017 to July 2018. Mr. Gorman earned his B.S. in Accounting from Villanova University.

How old is Robert Gorman?

Robert Gorman is 62, he's been the Director of Interpace Biosciences Inc since 2020. There are 3 older and 6 younger executives at Interpace Biosciences Inc. The oldest executive at Interpace Biosciences Inc is Stephen Sullivan, 73, who is the Chairman of the Board.

What's Robert Gorman's mailing address?

Robert's mailing address filed with the SEC is C/O INTERPACE BIOSCIENCES, INC., 300 INTERPACE PARKWAY, PARSIPPANY, NJ, 07054.

Insiders trading at Interpace Biosciences Inc

Over the last 9 years, insiders at Interpace Biosciences Inc have traded over $0 worth of Interpace Biosciences Inc stock and bought 94,105 units worth $353,961 . The most active insiders traders include Peter Kamin, Nat Krishnamurti a Graham G Miao. On average, Interpace Biosciences Inc executives and independent directors trade stock every 99 days with the average trade being worth of $48,561. The most recent stock trade was executed by Thomas W. Burnell on 21 May 2021, trading 10,855 units of IDXG stock currently worth $94,221.

What does Interpace Biosciences Inc do?

advancing patient care through molecular diagnostic testing. interpace diagnostics develops molecular diagnostic tests. our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis. you can be assured that all of the molecular tests we offer are driven by rigorous, validated science. we power the future of molecular diagnostics, delivering cutting-edge and much-needed mutational analysis that helps risk-stratify for thyroid, pancreatic, and other cancers to better inform treatment decisions. the unique molecular diagnostic tests we offer enable healthcare providers to avoid unnecessary surgeries and better assess the risk of cancer progression in their patients.

Interpace Biosciences Inc executives and stock owners

Interpace Biosciences Inc executives and other stock owners filed with the SEC include:

• Jack Stover,
  President, Chief Executive Officer, Director
• Dr. Thomas W. Burnell Ph.D.,
  Pres, CEO & Director
• Fortunato Rocca,
  Independent Director
• Joseph Keegan,
  Independent Director
• Eric Lev,
  Non-Executive Director
• Robert Gorman,
  Director
• Edward Chan,
  Director
• Fred Knechtel,
  Chief Financial Officer, Treasurer, Secretary
• Stephen Sullivan,
  Chairman of the Board
• Patrick Kane,
  VP & Corp. Controller
• Dr. Alidad Mireskandari M.B.A., Ph.D.,
  Chief Devel. Officer
• Dr. Sydney D. Finkelstein,
  Chief Scientific Officer
• Thomas John Freeburg Ph.D.,
  CFO, Treasurer & Sec.
• Nat Krishnamurti,
  Interim CFO
• Graham G Miao,
  CFO
• William Jheartland Advisors...,
  
• Harry Glorikian,
  Director
• 2018 Limited Partnership Am...,
  10% owner
• Thomas W. Burnell,
  President & CEO
• Peter Kamin,
  10% owner
• Laurence Mc Carthy,
  Director
• Felice Schnoll Sussman,
  Director
• Gregory Richard,
  Chief Commerical Officer
• James Early,
  
• Vijay Aggarwal,
  Director
• Christopher Mc Carthy,
  Chief Financial Officer